1Mirna Lechpammer,Josip Luka?,Stanislav Lechpammer,Dujo Kova?evi?,Massimo Loda,Zvonko Kusi?. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy[J] 2004,International Journal of Colorectal Disease(2):114～120
2Mary L. Disis,Keith L. Knutson,Kathy Schiffman,Kristine Rinn,Douglas G. McNeel. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer[J] 2000,Breast Cancer Research and Treatment(3):245～252
3Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005,5:341-354.
4Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res, 2009,315:557-571.
5Ugocsai K, Mandoky L, Tiszlavicz L, et al. Investigation of HER2 overexpression in non small cell lung cancer. Anticancer Res , 2005,25 : 3061-3066.
6Pupa SM, Menard S, Andreola S, et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res, 1993,53 : 5864-5866.
7Chapman CJ, Murray A, McElveen JE,et al. Autoantibodies in lung cancer:possibilities for early detection and subsequent cure. Thorax, 2008,63 : 228-233.
8Bei R, Masuelli L, Moriconi E,et al. Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oneogene, 1999,18:1267-1275.
9Fernandez-Madrid F, VandeVord PJ, Yang X, et al. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res, 1999,5 : 1393-1400.
10Kubo M, Ihn H, Kuwana M,et al. Anti-US snRNP antibody as a possible serological marker for scleroderma polymyositis overlap. Rheumatology (Oxford) , 2009,41 : 531-534.
